Overview
99mTc-MIRC213 SPECT/CT for the Detection of HER2-positive Breast Cancer
Status:
Recruiting
Recruiting
Trial end date:
2023-12-31
2023-12-31
Target enrollment:
0
0
Participant gender:
Female
Female
Summary
This is an open-label single photon emission tomography/computed tomography (SPECT/CT) study to investigate the imaging performance of 99mTc-MIRC213 in breast cancer patients. A single dose of 11.1-14.8Mega-Becquerel (MBq) per kilogram body weight 99mTc-MIRC213 will be injected intravenously. Visual and semiquantitative method will be used to assess the SPECT/CT images.Phase:
Early Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Peking Union Medical College Hospital
Criteria
Inclusion Criteria:- patients in suspicion of breast cancer by mammography or ultrasonography,and being
able to provide basic information and sign the written informed consent form
Exclusion Criteria:
- The exclusion criteria included claustrophobia, pregnancy, breastfeeding, kidney or
liver failure, inability to fulfill the study, and undergoing any preceding local or
systemic therapies that might interfere with HER2 binding.